At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 394 enrolled
Drug / intervention
13vPnC +8 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE
In Brief
A Phase 1 clinical trial evaluating Candidate-1, Candidate-2, and 7 other interventions for Pneumococcal Disease. Completed, enrolled 394 participants across 18 sites.
Detailed Summary
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartAug 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedAug 5, 2022
Enrollment StartAug 15, 2022
Primary CompletionOct 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 3.9 years ago
Interventions
Candidate-1other
Biological
Candidate-2other
Biological
Candidate-3other
Biological
Candidate-4other
Biological
Candidate-5other
Biological
Candidate-6other
Biological
Candidate Controlother
Biological
13vPnCbiological
13-valent pneumococcal conjugate vaccine
PCV15biological
15-valent pneumococcal conjugate vaccine